November 7, 2012
Eli Lilly Japan and Chugai Pharmaceutical announced on November 5 that they will terminate the comarketing of Evista (raloxifene), a treatment for osteoporosis in postmenopausal women, at the end of December 2012. Eli Lilly will be solely responsible for the...read more